102 related articles for article (PubMed ID: 8603009)
1. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM).
Kyrstsonis MC; Dedoussis G; Baxevanis C; Stamatelou M; Maniatis A
Br J Haematol; 1996 Feb; 92(2):420-2. PubMed ID: 8603009
[TBL] [Abstract][Full Text] [Related]
2. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
3. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
[TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma.
Kyrtsonis MC; Dedoussis G; Zervas C; Perifanis V; Baxevanis C; Stamatelou M; Maniatis A
Br J Haematol; 1996 May; 93(2):398-400. PubMed ID: 8639436
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.
Thaler J; Fechner F; Herold M; Huber H
Leuk Lymphoma; 1994 Jan; 12(3-4):265-71. PubMed ID: 8167557
[TBL] [Abstract][Full Text] [Related]
6. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
[TBL] [Abstract][Full Text] [Related]
7. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
8. IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis.
Mehtap O; Atesoglu EB; Tarkun P; Hacihanefioglu A; Dolasik I; Musul MM
J Postgrad Med; 2014; 60(2):141-4. PubMed ID: 24823512
[TBL] [Abstract][Full Text] [Related]
9. Determination of IL6, IL1, and IL4 in the plasma of patients with multiple myeloma.
Kiss TL; Lipton JH; Bergsagel DE; Meharchand JM; Jamal N; Minden MD; Messner HA
Leuk Lymphoma; 1994 Jul; 14(3-4):335-40. PubMed ID: 7950924
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.
Plante M; Rubin SC; Wong GY; Federici MG; Finstad CL; Gastl GA
Cancer; 1994 Apr; 73(7):1882-8. PubMed ID: 8137215
[TBL] [Abstract][Full Text] [Related]
11. In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors.
Sonneveld P; Schoester M; de Leeuw K
Br J Haematol; 1991 Dec; 79(4):589-94. PubMed ID: 1772780
[TBL] [Abstract][Full Text] [Related]
12. [A high serum level of interleukin-6 in a patient with aggressive multiple myeloma].
Abe Y; Muta K; Kato S; Sadamura S; Nishimura J; Nawata H; Takeichi N; Sakai K
Rinsho Ketsueki; 1991 Nov; 32(11):1458-62. PubMed ID: 1758053
[TBL] [Abstract][Full Text] [Related]
13. Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients.
Ibricevic-Balic L; Icindic-Nakas E; Hasic S; Kiseljakovic E; Sofo-Hafizovic A; Balic S
Med Arch; 2016 Dec; 70(6):429-432. PubMed ID: 28210014
[TBL] [Abstract][Full Text] [Related]
14. CD4+CD25+ cells in multiple myeloma related renal impairment.
Huang H; Luo Y; Liang Y; Long XD; Peng Y; Liu Z; Wen X; Jia M; Tian R; Bai C; Li C; Dong X
Sci Rep; 2015 Nov; 5():16565. PubMed ID: 26564056
[TBL] [Abstract][Full Text] [Related]
15. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ; Adachi I
Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
[TBL] [Abstract][Full Text] [Related]
16. Estimation of serum level of interleukin-17 and interleukin-4 in leprosy, towards more understanding of leprosy immunopathogenesis.
Abdallah M; Emam H; Attia E; Hussein J; Mohamed N
Indian J Dermatol Venereol Leprol; 2013; 79(6):772-6. PubMed ID: 24177608
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of serum IL-6 in patients with multiple myeloma].
Xing LJ; Xu Y; An G; Deng SH; Sui WW; Li F; Zhou DH; Zhao YZ; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1492-5. PubMed ID: 24370035
[TBL] [Abstract][Full Text] [Related]
18. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].
Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L
Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Bataille R; Jourdan M; Zhang XG; Klein B
J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
[TBL] [Abstract][Full Text] [Related]
20. Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma.
Shen CJ; Yuan ZH; Liu YX; Hu GY
J Int Med Res; 2012; 40(2):556-64. PubMed ID: 22613416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
